Evaluation of the quality of life and the efficacy of treatment after high power potassium-titanyl-phosphate (KTP) laser vaporization for patients with a prostate volume greater than 40cc

Korean Journal of Urology

Volumn 48, Issue 9, 2007, Pages 956-964

  Lee, Jong ^a   Kang, Seok Ho ^a   Kim, Je Jong ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Benign prostatic hyperplasia; Laser vaporization; Quality of life

Indexed keywords

PHOSPHATE; POTASSIUM; TITANIUM;

ACCURACY; ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DYSURIA; HEMATURIA; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LASER SURGERY; MALE; OPERATION DURATION; PATIENT SATISFACTION; POSTAL MAIL; POSTOPERATIVE PERIOD; POSTVOID RESIDUAL URINE VOLUME; PREOPERATIVE EVALUATION; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETROGRADE EJACULATION; SOUTH KOREA; STATISTICAL SIGNIFICANCE; TELEPHONE; THERAPY EFFECT; URETHRA STRICTURE; URINARY TRACT INFECTION; URINE FLOW RATE; URINE INCONTINENCE; URINE RETENTION;

EID: 34848855752     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2007.48.9.956     Document Type: Article

References (24)

1. Perrin P, Barnes R, Hadley H, Bergman RT. Forty years of transurethral prostatic resections. J Urol 1976;116:757-8
2. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: im-mediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141:243-7
3. Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP. Immediate and postoperative complications of transurethral prostatectomy in the 1990's. J Urol 1999;162:1307-10
4. Bouchier-Hayes DM, Anderson P, Van Appledorn S, Bugeja P, Costello AJ. KTP laser versus transurethral resection: early results of randomized trial. J Endourol 2006;20:580-5
5. Hwang EC, Joo JS, Min KD, Oh BR, Kang TW, Kwon DD, et al. A short-term comparative study on efficacy and safety of standard transurethral resection and high power (80W) potassium-titanyl-phosphate laser vaporization of the prostate. Korean J Urol 2005;46:1251-5
6. Sandhu JS, Ng C, Vanderbrink BA, Egan C, Kaplan SA, Te AE. High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology 2004;64: 1155-9
7. Lukacs B, Comet D, Grange JC, Thibault P. Construction and validation of a short-form benign prostatic hypertropby health-related quality-of-life questionnaire. BPH Group in General Practice. Br J Urol 1997;80:722-30
8. Hong JE, Choi HY, Hong SJ, Chung MK, Ahn TY, Rim JS, et al. Construction of a short form BPH specific health related quality of life scale: reliablility and validity tests. Korean J Urol 2001;42:1270-7
9. Rutkow IM. Urological operations in the United States: 1979 to 1984. J Urol 1986;135:1206-8
10. McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin 1994;8:1-17
11. Kuntz RM. Current role of lasers in the treatment of benign prostatic hyperplasia. Eur Urol 2006;49:961-9
12. Blute ML, Tomera KM, Hellerstein DK, McKiel CF Jr, Lynch JH, Regan JB, et al. Transurethral microwave thermotheraphy for management of benign prostatic hyperplasia results of the United Utates Prostatron Cooperative Study. J Urol 1993; 150:1591-6
13. Kaplan SA, Te AE. Transurethral electrovaporization of the prostate: a novel method for treating men with benign prostatic hyperplasia. Urology 1995;45:566-72
14. Jacques SL. Laser-tissue interactions. Photochemical, photothermal, and photomechanical. Surg Clin North Am 1992;72: 531-58
15. Te AE. The development of laser prostatectomy. BJU Int 2004;93:262-5
16. Malek RS, Kuntzman RS, Barrett DM. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 2005;174:1344-8
17. Reich O, Bachmann A, Siebels M, Hofstetter A, Stief CG, Sulser T. High power (80W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol 2005;173:158-60
18. Te AE, Malloy TR, Steins BS, Ulchaker JC, Nseyo UO, Hai MA. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. BJU Int 2006;97:1229-33
19. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Gefler J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999;53:473-80
20. Roehrborn CG. Meta-analysis of randomized clinical trials of finasteride. Urology 1998;51(Suppl 4A):46-9
21. Cho JS, Kim CI, Seong DH, Kim HS, Kim YS, Kim SJ, et al. Cat-off point of large prostate volume for the patients with benign prostatic hyperplasia. Korean J Urol 2005;46:1246-50
22. Hunter DJ, McKee M, Black NA, Sanderson CF. Health status and quality of life of British men with lower urinary tract symptoms: results from the SF-36. Urology 1995;45:962-71
23. Volkan T, Ihsan TA, Yilmaz O, Emin O, Selcuk S, Koray K, et al. Short term outcomes of high power (80W) potassium-titanyl-phosphate laser vaporization of the prostate. Eur Urol 2005;48:608-13
24. Bachmann A, Ruszat R, Wyler S, Reich O, Seifert HH, Müller A, et al. Photoselective vaporization of the prostate: the basel experience after 108 procedures. Eur Urol 2005;47:798-804